Biohaven Highlights Portfolio Progress at 43rd Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative and transformative therapies to treat individuals with rare and common diseases, today highlighted broad portfolio progress at the 43rd Annual J.P. Morgan Healthcare Conference, including positive Phase 1 data for BHV-1400, its highly differentiated investigational therapeutic for IgA nephropathy. BHV-1400 is a second generation TRAP™ degrader from its proprietary MoDE™ platform. A copy of the slide presentation is available on the Events and Presentations section of the Biohaven website.

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "While we are excited about the significant progress across our entire portfolio, the first-ever data of a TRAP degrader in humans is monumental and unparalleled. The ability to only remove aberrant proteins causing disease while leaving all other immune functioning intact will usher in a new era of precision immunology. As quickly as science can identify new disease-causing proteins, our technology can quickly advance treatments for patients. I am proud of our dedicated, passionate and gifted team's unrelenting drive to transform medical care for patients suffering from severe diseases."

Biohaven 2025 Portfolio Review and Anticipated Milestones

Biohaven is positioned to achieve significant milestones in 2025 across a broad spectrum of early- and late-stage programs targeting indications with high unmet need:

Molecular Degrader of Extracellular Proteins (MoDE) Platform

Biohaven's novel immune-modulating extracellular degrader platform harnesses selectivity, rapidity, and patient-friendly self-administration to remove disease-causing proteins from the body to potentially treat a wide range of diseases. Biohaven introduced next generation TRAP degraders, which are highly selective, each targeting a specific disease-causing protein for proteolysis. Four INDs for MoDE and next generation TRAP degrader molecules (targeting IgG1, IgG2, IgG4, Gd-IgA1, and β1AR autoantibodies) have been accepted by the FDA in 2024 with several additional investigational agents in development. Three assets have been dosed in Phase 1 trials with the fourth anticipated to be dosed in the first half of 2025.

The first-of-its-kind molecule, BHV-1300 is being developed for the treatment of common immune-mediated diseases, such as Graves' Disease and Rheumatoid Arthritis... Targeted IgG reductions (IgG1, IgG2, and IgG4, over IgG3) have been consistent with projected modeling. Phase 1 dose escalation is completing in 1H 2025, with Graves' Disease Phase 2 trial to initiate mid-year...

BHV-1400 and BHV-1600

Currently in Phase 1 clinical trials, represent the next generation TRAP degraders focused on selectively clearing very specific pathogenic antibodies, while sparing healthy immunoglobulin to preserve immune function. Data from the first, and lowest, dose cohort of BHV-1400 demonstrated clear differentiation from competitors in the IgA nephropathy space...

Upcoming milestones in the degrader program include:

Tova Gardin, M.D., M.P.P, Biohaven Chief Translational Officer, reflected on the recent results from the MoDE degrader platform...

BHV-2100

First-in-clinic, oral, selective TRPM3 antagonist that offers a novel, non-addictive treatment for migraine and neuropathic pain. Based on favorable pharmacokinetic and safety data...

BHV-7000

Selective activator of Kv7.2/7.3 potassium channels, a breakthrough target in neurology and neuropsychiatry with blockbuster potential...

Troriluzole

A novel glutamate modulator currently in Phase 3 development for Spinocerebellar ataxia (SCA) and obsessive-compulsive disorder (OCD)...

Taldefgrobep alfa

A novel myostatin inhibitor that is optimized to block both myostatin and activin A signaling...

BHV-8000

A highly selective, oral, brain-penetrant, selective TYK2/JAK1 inhibitor with broad potential for neurodegenerative and neuroinflammatory disorders...

Oncology antibody drug conjugate (ADC) portfolio

BHV-1510 (Trop2 ADC): Preliminary data from the initial Phase 1 study dosing cohorts...

About Biohaven

Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments...

Forward-looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995...